From PsychonautWiki
(Redirected from Hexen)
Jump to: navigation, search
Summary sheet: N-Ethylhexedrone
Chemical Nomenclature
Common names Hexen, Hex-en, NEH, Ethyl-Hexedrone
Substitutive name N-Ethylhexedrone, N-Ethyl-nor-hexedrone
Systematic name 2-(ethylamino)-1-phenylhexan-1-one
Class Membership
Psychoactive class Stimulant
Chemical class Cathinone
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold Common Heavy
1 - 2 - 5 - 10 - 20 mg
Light Strong
Threshold 1 - 2 mg
Light 2 - 5 mg
Common 5 - 10 mg
Strong 10 - 20 mg
Heavy 20 mg +
Total 1 - 4 hours
Onset 2 - 10 minutes
Peak 10 - 30 minutes
Offset 15 - 30 minutes
After effects 2 - 4 hours

Threshold Common Heavy
5 - 15 - 30 - 40 - 50 mg
Light Strong
Threshold 5 - 15 mg
Light 15 - 30 mg
Common 30 - 40 mg
Strong 40 - 50 mg
Heavy 50 mg +
Total 2 - 5 hours
Onset 2 - 8 minutes
Peak 30 - 90 minutes
Offset 1 - 4 hours
After effects 1 - 8 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

N-Ethylhexedrone (also known as hexen or NEH) is a novel stimulant of the cathinone class that produces classical stimulant effects such as stimulation, disinhibition, thought acceleration, and euphoria when administered. Its effects are believed to be caused by its activity as an NDRI (norepinephrine-dopamine reuptake inhibitor), although this has yet to be scientifically validated.[citation needed]

As with many of its research chemical cathinone predecessors, N-ethylhexedrone is known to come in the form of either a white powder or crystallized shards[citation needed] which users can ingest to produce a powerful, fast-acting but short-lived euphoric stimulant effects which are comparable to those produced by crack-cocaine, NEP and α-PVP-related compounds, particularly when they are insufflated or vaporized.[citation needed]

Like other substituted cathinones, N-ethylhexedrone has gained notoriety for its associated tendency to induce compulsive redosing and addictive behaviors in a seemingly significant percentage of its users as well the ability to readily induce paranoia, anxiety, various delusional states and stimulant psychosis when abused, taken too frequently or in excess.[citation needed]

N-Ethylhexedrone was first synthesized in 2011 but became widely available in the research chemical market during late 2015, upon which it rapidly gained popularity. It is a prominent example of a contemporary designer drug specifically chosen to mimic and/or replace the functional and structural features of its recently-controlled predecessors, which are sometimes imprecisely grouped together by the media as "bath salts".[citation needed]

Little research exists about both N-ethylhexedrone as well as its parent compound, hexedrone, particularly with regards to its toxicity, addiction, and abuse potential, although many anecdotal information and reports do exist can make more information to this compound than various others like hexedrone or a-PVP Due to its novelty and extremely short history of human usage, all information related to the use of this compound should be treated with caution.


N-Ethylhexedrone is a molecule of the cathinone chemical class. The term "substituted cathinone" refers to a broad array of substances based on cathinone, the principally active constituent of the khat plant. Cathinone is principally constituted of a amphetamine core (a phenethylamine core with an alkyl group attached to the alpha carbon) and an oxygen group attached to the beta carbon. Cathinones are also known as the beta-ketone (βk) (double-bonded oxygen to the β-carbon) analogs of amphetamines.

Notably, the cathinone backbone can be modified in three different places to create hundreds of possible compounds, which include substituents such as on the aromatic ring, the alpha carbon, or the amine group.[1]


Due to the lack of research regarding the substance, all proceeding discussion regarding the pharmacology of this compound derives from speculation based upon its structure and subjective effect similarities to other substituted cathinones especially NEP (N-ethyl-(nor)-pentedrone), pentedrone, a-PVP, and a-PHP and others.

N-ethylhexedrone most likely acts as both a powerful dopamine and norepinephrine reuptake inhibitor due to its substituted cathinone structure.[citation needed] This allows the endogenous neurotransmitters dopamine and norepinephrine to accumulate within the brain, resulting in extremely stimulating and euphoric effects.[citation needed]

The pharmacology of N-ethylhexedrone can perhaps be compared to the better known hexedrone. N-ethylhexedrone is an extended chain version of hexedrone, differing by a single carbon on the alpha-alkyl chain. It should be noted that extension of the carbon chain in this manner generally results in less potency than the parent compound. However, the addition of the ethyl group to the terminal amine (-NH2) group seems to counteract this and increase its potency significantly, much like is observed with NEP (N-Ethyl-(nor)-Pentedrone) compared to pentedrone.

Subjective effects

This subjective effect breakdown is a stub.

As such, it may contain incomplete or wrong information and is still in progress.

You can help by expanding it.

While the effects of hexen are often exaggerated, it is generally reported have more side effects when compared to mephedrone or NEP, which can lead to excessive redosing, sobriety delusions and toxicity, which can eventually lead to highly uncomfortable experiences. The effects of vaporized N-ethylhexedrone are reported to be much stronger and more euphoric with less side effects than when insufflated or taken orally, but extreme care should be taken with this route of administration due to the degree it promotes compulsive and reckless use.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Cognitive effects

Auditory effects

After effects
Aftereffects (3).svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational N-ethylhexedrone use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because N-ethylhexedrone has a very brief history of human usage.

Early anecdotal reports from those who have tried N-ethylhexedrone suggests that there do not seem to be any negative health effects attributed to simply trying it at low to moderate doses by itself and using it in a sparing and controlled fashion (but nothing can be completely guaranteed).

Some users have reported N-ethylhexedrone to be caustic to the nasal membrane when it is insufflated.[citation needed]

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

As with other stimulants, the chronic use of N-ethylhexedrone can be considered moderately addictive with a high potential for abuse and seems to be readily liable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of N-ethylhexedrone develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the total absence of further consumption). N-ethylhexedrone presents cross-tolerance with all noradrenergic and dopaminergic stimulants, meaning that after the consumption of N-ethylhexedrone all stimulants will have a reduced effect.


Main article: Stimulant psychosis

Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., anxiety andparanoia, hallucinations, or delusions).[2] A review on treatment for (dextro)amphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[3][4] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[5]

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • United Kingdom - N-Ethylhexedrone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.[7]
  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[8]
  • Sweden - N-Ethylhexedrone was classified as an illegal narcotic in Sweden on June 21st, 2016.[9]

See also

External links


  1. Liu, C., Jia, W., Li, T., Hua, Z., & Qian, Z. (n.d.). Identification and analytical characterization of nine synthetic cathinone derivatives N-ethylhexedrone, 4-Cl-pentedrone, 4-Cl--EAPP, propylone, N-ethylnorpentylone, 6-MeO-bk-MDMA, -PiHP, 4-Cl--PHP, and 4-F--PHP. https://doi.org/10.1002/dta.2136
  2. Treatment for amphetamine psychosis | [1]
  3. Treatment for amphetamine psychosis | [2]
  4. Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  5. Treatment for amphetamine psychosis | [3]
  6. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
  7. United Kingdom. (2010). Misuse of Drugs Act 1971 (S.I. 2010/1207). London: The Stationery Office Limited. Retrieved February 9, 2018, from https://www.legislation.gov.uk/uksi/2010/1207/made
  8. http://portal.anvisa.gov.br/documents/33868/3233596/56+-+RDC+N%C2%BA+159-2017-DOU.pdf/27be30ee-3884-46fe-b7ba-ae2f94b74693
  9. 31 nya ämnen kan klassas som narkotika eller hälsofarlig vara | https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/juni/31-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara/